D. Booser

发表

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

J. Ross, K. Hess, G. Hortobagyi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Yuan Qi, W. Fraser Symmans, Lajos Pusztai, 2012, Breast Cancer Research and Treatment.

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

J. Stec, M. Ayers, K. Hess, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

J. Stec, M. Ayers, K. Hess, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

L. Esserman, G. Hortobagyi, L. Pusztai, 2011, JAMA.

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2002, Cancer Chemotherapy and Pharmacology.

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.

G. Hortobagyi, S. Singletary, D. Booser, 1995, Surgical oncology clinics of North America.

Anthracycline Antibiotics in Cancer Therapy

G. Hortobagyi, D. Booser, Daniel J. Booser, 1994, Drugs.

Phase I I, R andomized, D ouble-Blind S tudy o f T wo D ose L evels of A rzoxifene i n P atients W ith L ocally A dvanced o r M etastatic Breast C ancer

C. Hudis, D. Booser, A. Buzdar, 2003 .

Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.

E. Bruera, G. Hortobagyi, L. Pusztai, 2004, Cytokine.

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2002, Cancer Chemotherapy and Pharmacology.

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.

G. Hortobagyi, K. Hunt, V. Valero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark

D. Booser, 2011 .

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

G. Hortobagyi, N. Sneige, V. Valero, 2011, The oncologist.

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.

G. Hortobagyi, D. Booser, R. Wendt, 2009, Clinical breast cancer.

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

G. Hortobagyi, E. Jonasch, D. Booser, 2003, Blood.

Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer.

D. Booser, M. Valdivieso, H. Barkley, 1985, International journal of radiation oncology, biology, physics.

Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1

G. Hortobagyi, V. Valero, D. Booser, 2006 .

Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin1

Herbert, D. Booser, A. Buzdar, 2006 .

Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.

G. Hortobagyi, D. Booser, A. Buzdar, 1994, Advances in experimental medicine and biology.

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

G. Hortobagyi, G. Gladish, D. Booser, 2012, Cancer.

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

G. Hortobagyi, N. Ibrahim, D. Booser, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antineoplastic Chemotherapy of Advanced Lung Cancer

D. Booser, G. Bodey, M. Valdivieso, 1982 .

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?

V. Valero, D. Booser, R. Theriault, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

G. Hortobagyi, D. Booser, 1994, Drugs.

Management of breast cancer during pregnancy using a standardized protocol.

D. L. Berry, G. Hortobagyi, S. Singletary, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.

G. Hortobagyi, V. Valero, D. Booser, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

G. Hortobagyi, H. Gibbs, V. Valero, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation

R. Bast, G. Hortobagyi, V. Valero, 2001, Cancer investigation.

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 2002, Ophthalmology.

Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.

V. Valero, D. Booser, B. Esmaeli, 2001, Ophthalmology.

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

W. Woodward, G. Babiera, T. Buchholz, 2013, Radiation Oncology.

Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases

G. Hortobagyi, V. Valero, D. Booser, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3‐times‐daily regimen to treat patients with recurrent metastatic breast cancer

G. Hortobagyi, D. Booser, W. Heim, 2010, Cancer.

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.

G. Hortobagyi, L. Pusztai, W. Symmans, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd I I S tudy o f E xisulind i n C ombination W ith Capecitabine i n P atients W ith M etastatic B reast C ancer

G. Hortobagyi, L. Pusztai, W. Symmans, 2003 .

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

G. Hortobagyi, H. Gibbs, V. Valero, 1993, Journal of the National Cancer Institute. Monographs.

Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease.

G. Hortobagyi, K. Hunt, T. Buchholz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of breast cancer during pregnancy using a standardized protocol.

D. L. Berry, G. Hortobagyi, S. Singletary, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

K. Hess, G. Hortobagyi, L. Pusztai, 2012, Breast Cancer Research and Treatment.

Phase II Study of Recombinant α‐Interferon (rIFNα) and Continuous‐Infusion 5‐Fluorouracil in Metastatic Breast Cancer

G. Hortobagyi, D. Booser, R. Theriault, 1995 .

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer.

G. Hortobagyi, D. Booser, R. Theriault, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma

G. Hortobagyi, F. Ames, V. Valero, 2003, Cancer.

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Yuan Qi, Jie Zhang, Christos Hatzis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

E. Winer, G. Hortobagyi, D. Booser, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Terry L. Smith, D. Berry, G. Hortobagyi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Terry L. Smith, G. Hortobagyi, L. Pusztai, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

A. Viale, C. Sotiriou, W. Fraser Symmans, 2019, npj Breast Cancer.

Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Melissa Bondy, Kristine R Broglio, G. Hortobagyi, 2008, Journal of the National Cancer Institute.

Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer

D. Booser, M. Valdivieso, D. Carr, 1984, Journal of Neuro-Oncology.

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer

G. Hortobagyi, K. Hunt, T. Buchholz, 2008, Clinical Cancer Research.

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors

Leming Shi, Weiwei Shi, Mauro Delorenzi, 2010, Breast Cancer Research.

A nonreplicating adenoviral vector that contains the wild‐type p53 transgene combined with chemotherapy for primary breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2006, Cancer.

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

N. Sneige, D. Booser, Y. Gong, 2005, Cancer.

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Roman Rouzier, Lajos Pusztai, G. Hortobagyi, 2005, Cancer.

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

D. Booser, R. Kurzrock, F. Janku, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel in the multimodality treatment for inflammatory breast carcinoma

G. Hortobagyi, N. Sneige, V. Valero, 2001, Cancer.

Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.

G. Hortobagyi, S. Singletary, F. Ames, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy

G. Hortobagyi, S. Singletary, V. Valero, 2000, Cancer.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Terry L. Smith, G. Hortobagyi, S. Singletary, 2000, Journal of the National Cancer Institute.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

P. Brown, V. Valero, N. Ibrahim, 2019, British Journal of Cancer.

G6PD Toronto

D. Booser, J. Crookston, M. Lin, 2004, Biochemical Genetics.

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Yuan Qi, Lajos Pusztai, Charles Coutant, 2011, Journal of the National Cancer Institute.

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Terry L. Smith, G. Hortobagyi, L. Pusztai, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

Terry L. Smith, D. Berry, G. Hortobagyi, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

G. Hortobagyi, V. Valero, D. Booser, 2000, Cancer.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

G. Hortobagyi, S. Singletary, F. Ames, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective E valuation o f P aclitaxel V ersus C ombination Chemotherapy W ith F luorouracil, D oxorubicin, and C yclophosphamide a s N eoadjuvant T herapy i n P atients With O perable B reast C ancer

G. Hortobagyi, S. Singletary, F. Ames, 1999 .

Taxol in metastatic breast cancer the MD Anderson Cancer Center experience

G. Hortobagyi, H. Gibbs, V. Valero, 1994 .

Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy.

C. Sotiriou, C. Desmedt, A. Harris, 2005 .

Phase I trail of droloxifene in patients with metastatic breast cancer

G. Hortobagyi, D. Booser, R. Theriault, 2004, Cancer Chemotherapy and Pharmacology.

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

A. Viale, C. Sotiriou, W. Fraser Symmans, 2019, npj Breast Cancer.

Genomic index of sensitivity to endocrine therapy for breast cancer.

Peter Regitnig, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

D. Esseltine, J. Stec, G. Hortobagyi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β

R. Bast, G. Hortobagyi, V. Valero, 2018, Investigational New Drugs.

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

G. Hortobagyi, L. Pusztai, V. Valero, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of deoxyspergualin in metastatic breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2004, Investigational New Drugs.

Treatment of locally advanced breast cancer.

G. Hortobagyi, D. Booser, G N Hortobagyi, 1992, Seminars in oncology.

Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non‐small cell lung cancer

D. Booser, M. Valdivieso, D. Carr, 1989, Cancer.

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

G. Mills, K. Hess, V. Valero, 2016 .

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.

C. Hudis, L. Norton, D. Booser, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer.

D. Booser, M. Valdivieso, D. Carr, 1988, International journal of radiation oncology, biology, physics.

A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

K. Hess, G. Hortobagyi, V. Valero, 2014, Cancer.

Phase II trial of 10-EDAM in the treatment of metastatic breast cancer

G. Hortobagyi, D. Booser, A. González-Angulo, 2007, Cancer Chemotherapy and Pharmacology.

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

W. Woodward, G. Babiera, T. Buchholz, 2013, Radiation oncology.

Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting.

K. Hess, G. Hortobagyi, V. Valero, 2012 .

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2010, Cancer.

Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 2008, Clinical breast cancer.

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

Razelle Kurzrock, D. Booser, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Women age < or = 35 years with primary breast carcinoma: disease features at presentation.

Kristine Broglio, G. Hortobagyi, V. Valero, 2005, Cancer.

Women age ≤ 35 years with primary breast carcinoma

G. Hortobagyi, V. Valero, D. Booser, 2005 .

High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study.

Diane D. Liu, E. Bruera, K. Hess, 2019, Journal of Clinical Oncology.

Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2006, Cancer.

A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer

V. Valero, D. Booser, R. Theriault, 2004, Clinical Cancer Research.

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.

R. Bast, G. Hortobagyi, V. Valero, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer

G. Hortobagyi, V. Valero, D. Booser, 2005, Drugs in R&D.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

P. Brown, V. Valero, N. Ibrahim, 2019, British Journal of Cancer.

Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

E. Winer, G. Hortobagyi, D. Booser, 2010 .

Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma

G. Hortobagyi, V. Valero, D. Booser, 2002, Cancer.

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

N. Ibrahim, D. Booser, D. Tripathy, 2023, Cancer.

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

C. Hudis, D. Booser, A. Buzdar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis

G. Hortobagyi, V. Valero, D. Booser, 2004 .

Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2005 .

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Y. Qi, G. Hortobagyi, L. Pusztai, 2011, Journal of the National Cancer Institute.

Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.

G. Hortobagyi, V. Valero, D. Booser, 1995, Cancer research.

Phase I study of liposomal annamycin

G. Hortobagyi, D. Booser, R. Perez-soler, 2000, Cancer Chemotherapy and Pharmacology.

Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.

D. Booser, B. Issell, M. Valdivieso, 1984, Cancer treatment reports.

Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer

D. Booser, G. Bodey, M. Valdivieso, 1984, American Journal of Clinical Oncology.

Phase I S tudy o f S tealth L iposomal D oxorubicin i n Combination W ith G emcitabine i n t he T reatment o f Patients W ith M etastatic B reast C ancer

R. Bast, G. Hortobagyi, V. Valero, 2001 .

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Y. Qi, G. Hortobagyi, L. Pusztai, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers

G. Hortobagyi, L. Pusztai, W. Symmans, 2008 .

Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.

N. Sneige, D. Booser, J. Litton, 2023, European journal of breast health.